Slow implementation of mifepristone medical termination of pregnancy in Quebec, Canada: a qualitative investigation

References

• Abortion Rights Coalition of Canada, ‘Statistics - Abortion in Canada; 2019’. Available from: https://www.arcc-cdac.ca/backrounders/statistics-abortion-in-canada.pdf
   Google Scholar
• Statistics Canada, ‘Annual demographic estimates: Canada, provinces and territories. table 2.1-1 annual population estimates by age group and sex at July 1, provincial perspective - Canada’. ; 2012. Available from: https://www150.statcan.gc.ca/n1/en/pub/91-215-x/91-215-x2012000-eng.pdf?st=_a1cZDZ1
   Google Scholar
• Norman WV, Guilbert E, Okpaleke C, et al. Abortion health services in Canada: results of a 2012 national survey. Can Fam Physician Med Fam Can. 2016;62(4):e209–e217.
   PubMed Web of Science ®Google Scholar
• Guilbert ER, Hayden AS, Jones HE, et al. First-trimester medical abortion practices in Canada: national survey. Can Fam Physician Med Fam Can. 2016;62(4):e201–e208.
   PubMed Web of Science ®Google Scholar
• Louise Desmarais. Québécoise deboutte! In: Personal and political: stories from the women’s health movement 1960–2010. Toronto (Canada): Lorraine Greaves; 2018. p. 376.
   Google Scholar
• Health Canada. Health Canada new drug authorizations: 2015 highlights - new active substances authorized with a priority review; 2015. Available from: https://www.canada.ca/en/health-canada/services/publications/drugs-health-products/health-canada-new-drug-authorizations-2015-highlights.html
   Google Scholar
• Linepharma International Limited & Celopharma Inc. MifegymisoPR - product monograph including patient medication information; 2015. Available from: http://celopharma.com/
   Google Scholar
• College of Pharmacists of British Columbia. Mifegymiso more accessible to pharmacists in BC; 2017. [updated 2017 May 19]. Available from https://www.bcpharmacists.org/readlinks/mifegymiso-now-more-accessible-pharmacists-bc
   Google Scholar
• Health Canada, Government of Canada. MIFEGYMISO (mifepristone and misoprostol tablets) - updates to product monograph and risk management plan; 2017.Available from: https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/65030a-eng.php
   Google Scholar
• Guilbert E, Costescu D, Dunn S, et al. Medical abortion training program - online training program. Soc Obstet Gynecol Can; 2017. Available from: https://sogc.org/fr/fr/rise/Events/event-display.aspx?EventKey=MATP_FR&WebsiteKey=11b610da-4e07-4e4a-8e67-ddddccf52e69
   Google Scholar
• Collège des médecins du Québec. L’interruption volontaire de grossesse pratiquée à l’aide de la pilule abortive - Directives cliniques; 2017. Available from http://www.cmq.org/publications-pdf/p-1-2017-12-13-fr-pilule-abortive-directives-cliniques-dec-2017.pdf
   Google Scholar
• Prochaska JO, DiClemente, CC. Stages and processes of self-change of smoking: toward an integrative model of change. J Consult Clin Psychol. 1983;51(3):390–395.
   PubMed Web of Science ®Google Scholar
• Rogers EM. Diffusion of innovation. 5th ed. New York (NY): Free Press; 2003.
   Google Scholar
• Greenhalgh T, Robert G, Macfarlane F, et al. Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Q. 2004;82(4):581–629.
   PubMed Web of Science ®Google Scholar
• Norman WV, Munro S, Brooks M, et al. Could implementation of mifepristone address Canada’s urban-rural abortion access disparity? A mixed methods implementation study protocol. BMJ Open. 2019.9:e028443é.
   PubMed Web of Science ®Google Scholar
• Wagner MS, Munro S, Wilcox ES, et al. Barriers and facilitators to the implementation of first trimester medical abortion with mifepristone in the province of Quebec: a qualitative investigation. J Obstet Gynaecol Can. 2019. Available from: https://www.jogc.com/article/S1701-2163(19)30979-X/pdf
   Web of Science ®Google Scholar
• Devane C, Renner RM, Munro S, et al. Implementation of mifepristone medical abortion in Canada: pilot and feasibility testing of a survey to assess facilitators and barriers. Pilot Feasibility Stud. 2019;5:126.
   PubMedGoogle Scholar
• Miles MB, Huberman AM, Analyse des données qualitatives. 2e éd. Bruxelles, Belgique: De Boeck Université s.a.; 2003.
   Google Scholar
• Jones RK, Henshaw SK. Mifepristone for early medical abortion: experiences in France, Great Britain and Sweden. Perspect Sex Reprod Health. 2002;34(3):154–161.
   PubMed Web of Science ®Google Scholar
• Hulme-Chambers A, Clune S, Tomnay J. Medical termination of pregnancy service delivery in the context of decentralization: social and structural influences. Int J Equity Health 2018;17(1):172.
   PubMedGoogle Scholar
• Doran F, Nancarrow S. Barriers and facilitators of access to first-trimester abortion services for women in the developed world: a systematic review. J Fam Plann Reprod Health Care. 2015;41(3):170–180.
   PubMedGoogle Scholar
• Daoust-Boisvert A. Un accès à un médecin de famille à géométrie variable. Le Devoir. 2018. Available from: https://www.ledevoir.com/societe/sante/532490/medecin-de-famille-un-acces-a-geometrie-variable
   Google Scholar
• Singh S, Remez L, Sedgh G, et al. Abortion worldwide 2017 - uneven progress and unequal access. New York (NY): Guttmacher Institute; 2017. Available from: https://www.guttmacher.org/report/abortion-worldwide-2017
   Google Scholar
• Linepharma international Ltd and Celopharma Inc. MifegymisoPR - product monograph including patient medication information; 2019. Available from: https://pdf.hres.ca/dpd_pm/00050659.PDF
   Google Scholar
• Collège des médecins du Québec. Pilule abortive: quelques précisions supplémentaires’ 24 mai 2018. Available from: http://www.cmq.org/nouvelles-pdf/n-3-2018-05-24-fr-pilule-abortive-precisions-supp.pdf?t=1579193648701.
   Google Scholar
• Collège des médecins du Québec. Le médecin, la télémédecine et les technologies de l’information et de la communication - Guide d’exercice; 2015. Available from: http://www.cmq.org/nouvelle/fr/guide-sur-telemedecine-tic.aspx
   Google Scholar
• Guttmacher Institute. State abortion policy review landscape: from hostile to supportive; 2019 Available from: https://www.guttmacher.org/article/2019/08/state-abortion-policy-landscape-hostile-supportive.
   Google Scholar
• National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division. Board on health care services, board on population health and public health practice, and committee on reproductive health services: assessing the safety and quality of abortion care in the U.S. The Safety and Quality of Abortion Care in the United States. Washington (DC): National Academies Press (US); 2018.
   Google Scholar
• Costescu D, Guilbert E, Bernardin J, et al. Medical Abortion. J Obstet Gynaecol Can. 2016;38(4):366–389.
   PubMed Web of Science ®Google Scholar
• Medical management of abortion. Geneva: World Health Organisation; 2018. Available from: https://www.who.int/reproductivehealth/publications/medical-management-abortion/en/
   Google Scholar
• ACOG. ACOG practice bulletin. Clinical management guidelines of obstetrician-gynecologists. Number 67, October 2005. Medical management of abortion. Obstet Gynecol. 2005;106(4):871–882.
   PubMedGoogle Scholar
• Raymond EG, Tan YL, Comendant R, et al. Simplified medical abortion screening: a demonstration project. Contraception. 2018;97(4):292–296.
   PubMed Web of Science ®Google Scholar
• Averbach S, Puri M, Blum M, et al. Gestational dating using last menstrual period and bimanual exam for medication abortion in pharmacies and health centers in Nepal. Contraception. 2018;98(4):296–300.
   PubMed Web of Science ®Google Scholar
• Bracken H, Clark W, Lichtenberg ES, et al. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol. BJOG Int J Obstet Gynaecol. 2011;118(1):17–23.
   PubMed Web of Science ®Google Scholar
• Barnard S, Kim C, Park MH, et al. Doctors or mid-level providers for abortion. Cochrane Database Syst Rev. 2015;7:CD011242. DOI: 10.1002/14651858.CD011242.pub2.
   PubMed Web of Science ®Google Scholar
• Gomperts R, Jelinska K, Davies S, et al. Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where ther is no access to safe services. BJOG. 2008;115(9):1171–1175.
   PubMed Web of Science ®Google Scholar
• Grossman D, Grindlay K. Safety of medical abortion provided through telemedicine compared with in Person. Obstet Gynecol. 2017;130(4):778–782.
   PubMed Web of Science ®Google Scholar
• Labrecque M. Nombre de cliniques de planification des naissances au Québec offrant l’avortement médical avec la mifépristone et le misoprostol. Fédération québécoise pour le planning des naissances;2019 (private communication).
   Google Scholar
• Celopharma. Customer segmentation by province; 2019. Available from: http://celopharma.com/en/contact/
   Google Scholar
• Institut national de santé publique du Québec. Infocentre. Nombre et taux d’interruption volontaire de grossesse pour les femmes âgées de 14-49 ans, 1995–2017; 2017.
   Google Scholar
• Jatlaoui TC, Shah J, Mandel MG, et al. Abortion surveillance - United States, 2014. Morb Mortal Wkly Rep. 2002;66(25):1–44.
   Google Scholar
• Health Canada approves updates to Mifegymiso prescribing information: Ultrasound no longer mandatory [Internet]. Health Canada, Government of Canada; 2019 [cited 2019 Jun 7]. Available from https://www.canada.ca/en/sr/srb.html?cdn=canada&st=s&num=10&langs=en&st1rt=1&s5bm3ts21rch=x&q=Mifegymiso%2C+2019&_charset_=UTF-8&wb-srch-sub=
   Google Scholar
• Collège des médecins du Québec. Pilule abortive: quelques précisions supplémentaires [Internet]; 2018 [cited 2019 May 1]. Available from http://www.cmq.org/nouvelle/fr/pilule-abortive-precisions-supp.aspx
   Google Scholar
• Collège des médecins du Québec. Code de déontologie des médecins [Internet]; 2015 [cited 2019 Apr 17]. Available from http://www.cmq.org/publications-pdf/p-6-2015-01-07-fr-code-de-deontologie-des-medecins.pdf?t=1555534075874
   Google Scholar
• Projet de loi no 41 (2011, chapitre 37) Loi modifiant la Loi sur la pharmacie Gouvernement du Québec. Adopté le 8 décembre 2011. Sanctionné le 9 décembre 2011 [cited 2019 Apr 17]. Available from http://www.assnat.qc.ca/fr/travaux-parlementaires/projets-loi/projet-loi-41-39-2.html
   Google Scholar